Piper Jaffray Reiterates Neutral on Quest Diagnostics (DGX) Following Announced Quest-Oxford Deal
Tweet Send to a Friend
Piper Jaffray analyst, William Quirk, reiterated a Neutral rating and $110.00 price target on Quest Diagnostics (NYSE: DGX) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
